EUVIMEDEUVIMED entdecken
Crossref

Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker

Zeenat Mirza iD

Current Medicinal Chemistry · 2024

DOI: 10.2174/0929867330666230516102017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Medicinal Chemistry, 2024. Verfasst von Zeenat Mirza. Beteiligte Einrichtung: King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Survivin, Breast Neoplasms, Biomarkers, Tumor, Transcriptome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: King Abdulaziz University, Deanship of Scientific Research (DSR), King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is the leading cause of cancer-related mortality among women worldwide. Advanced stages are usually obstinate with chemotherapy, resulting in a poor prognosis; however, they are treatable if diagnosed early.

Objective

Identifying biomarkers that can detect cancer early or have therapeutic significance is imperative.

Methods

Herein, a comprehensive bioinformatics-based transcriptomics study of breast cancer for identifying differentially expressed genes (DEGs), followed by a screening of potential compounds by molecular docking, was performed. Genome-wide mRNA expression data of breast cancer patients (n=248) and controls (n=65) were retrieved from the GEO database for meta-analysis. Statistically significant DEGs were used for enrichment analysis based on ingenuity pathway analysis and protein-protein network analysis.

Results

A total of 3096 unique DEGs (965 up-regulated and 2131 down-regulated) were mapped as biologically relevant. The most upregulated genes were COL10A1, COL11A1, TOP2A, BIRC5 (survivin), MMP11, S100P, RARA, and the most downregulated genes were ADIPOQ, LEP, CFD, PCK1 and HBA2. Transcriptomic and molecular pathway analyses identified BIRC5/survivin as a significant DEG. Kinetochore metaphase signaling is recognized as a prominent dysregulated canonical pathway. Protein-protein interaction study revealed that KIF2C, KIF20A, KIF23, CDCA8, AURKA, AURKB, INCENP, CDK1, BUB1 and CENPA are BIRC5-associated proteins. Molecular docking was performed to exhibit binding interactions with multiple natural ligands.

Conclusion

BIRC5 is a promising predictive marker and a potential therapeutic target in breast cancer. Further large-scale studies are required to correlate the significance of BIRC5 in breast cancer, leading to a step toward the clinical translation of novel diagnostic and therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SurvivinBreast NeoplasmsBiomarkers, TumorTranscriptomeHumansFemaleMolecular Docking SimulationComputational BiologyGene Expression Profiling

Stichwörter der Autor:innen

Breast cancerbiomarkersdockingpathway analysissurvivintranscriptomics

Substanzen

SurvivinBiomarkers, TumorBIRC5 protein, human

Autor:innen und Institutionen

  • King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

ORCID-Profile: Zeenat Mirza

Förderung

  • King Abdulaziz University
  • Deanship of Scientific Research (DSR), King Abdulaziz University

Zitieren

APA

Mirza, Z. (2024). Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker. Current Medicinal Chemistry. https://doi.org/10.2174/0929867330666230516102017

Vancouver

Mirza Z. Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker. Current Medicinal Chemistry. 2024. doi:10.2174/0929867330666230516102017

BibTeX
@article{Mirza2024,
  author = {Mirza, Zeenat},
  title = {Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker},
  journal = {Current Medicinal Chemistry},
  year = {2024},
  doi = {10.2174/0929867330666230516102017}
}
Kostenlos starten →